Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection

Hepatology

Volumn 63, Issue 5, 2016, Pages 1471-1480

  Fan, Lin ^a   Owusu Edusei, Kwame ^a   Schillie, Sarah F ^a   Murphy, Trudy V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEPATITIS B; HOSPITAL DISCHARGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; PERINATAL INFECTION; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; THIRD TRIMESTER PREGNANCY; TREATMENT PLANNING; VIRUS LOAD; ADULT; BLOOD; COST BENEFIT ANALYSIS; IMMUNOLOGY; PREVENTION AND CONTROL; VACCINATION; VERTICAL TRANSMISSION;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNOGLOBULINS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 84963815216     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28310     Document Type: Article

References (50)

1. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, Bell B. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010;202:192-201.
2. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012;56:422-433.
3. Din ES, Wasley A, Jacques-Carroll L, Sirotkin B, Wang S. Estimating the Number of births to hepatitis B virus-infected women in 22 states, 2006. Pediatr Infect Dis J 2011;30:575-579.
4. Fan L, Owusu-Edusei K, Jr., Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol 2014;123:929-937.
5. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis-b virus transmission by immunization-an economic-analysis of current recommendations. JAMA 1995;274:1201-1208.
6. Pan CV, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, Tong MJ. An Algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012;10:452-459.
7. Ott JJ, Stevens GA, Wiersma ST. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis 2012;12:131.
8. Lee CF, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systemic review and meta-analysis. BMJ 2006;332:328-332.
9. Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics 2013;131:e1135-e1143.
10. Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002;20:3739-3743.
11. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
12. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475.
13. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
14. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-450.
15. Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol 2014;20:7169-7180.
16. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218-1229.
17. Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Digest Dis Sci 2012;57:2423-2429.
18. Pan CV, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:520-526.
19. Shi ZJ, Yang YB, Ma L, Li XM, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus a systematic review and meta-analysis. Obstet Gynecol 2010;116:147-159.
20. Komatsu H, Inui A, Sogo T, Tsunoda T, Fujisawa T. Chronic hepatitis B virus infection in children and adolescents in Japan. J Pediatr Gastroenterol Nutr 2015;60:99-104.
21. Popalis C, Yeung LT, Ling SC, Ng V, Roberts EA. Chronic hepatitis B virus (HBV) infection in children: 25 years' experience. J Viral Hepat 2013;20:e20-e26.
22. WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015. Available at: http://apps.who.int/medicinedocs/documents/s21813en/s21813en.pdf. Accessed August 22, 2015.
23. Arias E. United States life tables, 2008. 2012. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_03.pdf. Accessed November 11, 2015.
24. Bortolotti F, Jara P, Crivellaro C, Hierro L, Cadrobbi P, Frauca E, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998;29:184-190.
25. Iorio R, Giannattasio A, Cirillo F, D' Alessandro L, Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007;45:943-949.
26. Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006;43:556-562.
27. Davison S. Management of chronic hepatitis B infection. Arch Dis Child 2014;99:1037-1042.
28. Della Corte C, Nobili V, Comparcola D, Cainelli F, Vento S. Management of chronic hepatitis B in children: an unresolved issue. J Gastroenterol Hepatol 2014;29:912-919.
29. Fan L, Owusu-Edusei K, Jr., Schillie SF, Murphy TV. Antiviral treatment among pregnant women with chronic hepatitis B. Infect Dis Obstet Gynecol 2014;2014:546165.
30. Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The national Perinatal Hepatitis B Prevention Program, 1994-2008. Pediatrics 2012;129:609-616.
31. Kubo A, Shlager L, Marks AR, Lakritz D, Beaumont C, Gabellini K, Corley DA. Prevention of vertical transmission of hepatitis B: an observational study. Ann Intern Med 2014;160:828-835.
32. Schillie S, Walker T, Veselsky S, Crowley S, Dusek C, Lazaroff J, et al. Outcomes of infants born to women infected with hepatitis B. Pediatrics 2015;135:e1141-e1147.
33. Shi ZJ, Li XM, Ma L, Yang YB. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis. Int J Infect Dis 2010;14:E622-E634.
34. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, et al. Yeast-recombinant hepatitis-b vaccine-efficacy with hepatitis-b immune globulin in prevention of perinatal hepatitis-b virus transmission. JAMA 1987;257:2612-2616.
35. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012;19:E18-E25.
36. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190:489-492.
37. Yuan J, Lin J, Xu A, Li H, Hu B, Chen J, et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study. J Viral Hepat 2006;13:597-604.
38. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, Spiegel BM. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-2089.
39. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004;38(10 Suppl 3):S144-S147.
40. United States Department of Labor. Consumer price indexes-all urban consumers. Washington, DC: Bureau of Labor Statistics, United States Department of Labor; 2011.
41. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276:1339-1341.
42. Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, et al. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci 2015;60:260-268.
43. Tohme RA, Bulkow L, Homan CE, Negus S, McMahon BJ. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010. J Clin Virol 2013;58:396-400.
44. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, Liaw YF. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997;145:1039-1047.
45. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011;26:628-638.
46. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
47. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010;138:1747-1754.
48. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45-S55.
49. New York Post. Zip code can affect likelihood of getting liver transplant-United Network for Organ Sharing working to make system more fair. In: New York Post, news section, August 20, 2013. Available at: http://nypost.com/2013/08/20/zip-code-can-affect-likelihood-of-getting-liver-transplant-united-network-for-organ-sharing-working-to-make-system-more-fair/. Accessed November 11, 2015.
50. Sawyer MH, Hoerger TJ, Murphy TV, Schillie SF, Hu D, Spradling PR, et al. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP) (Reprinted from MMWR, vol 60, pg 1709-1711, 2011). JAMA 2012;307:659-662.